NCT00485732 - A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years | Biotech Hunter

Enrollment

225

Participants

Timeline

Start Date

June 11, 2007

Primary Completion Date

March 30, 2008

Study Completion Date

March 30, 2008

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL

HPV-16/18 VLP/AS04 vaccine (Cervarix TM)

Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.

BIOLOGICAL

Placebo

Three doses of placebo administered intramuscularly according to a 0, 1, 6-month schedule.

Trial Locations (6)